CDR-Life Inc.

CDR-Life Inc.

Biotechnologieforschung

Horgen, Zurich 4.009 Follower:innen

REDEFINING ANTIBODY THERAPIES

Info

CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to a wide range of cancer antigens. We are leveraging this platform to advance a pipeline of potent and selective TCE therapeutics targeting intracellular and surface tumor antigens. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to empower patients’ own immune systems to eliminate tumors.

Branche
Biotechnologieforschung
Größe
51–200 Beschäftigte
Hauptsitz
Horgen, Zurich
Art
Privatunternehmen
Gegründet
2017
Spezialgebiete
Antibody fragments, Ophthalmology, Immuno-oncology, Biotechnology, Drug development, Entrepreneurship, Team culture, Targeted immuno-therapies, Oncology und Cancer

Orte

Beschäftigte von CDR-Life Inc.

Updates

Ähnliche Seiten